AU2022261654A1 - Modified polypeptides and uses thereof - Google Patents
Modified polypeptides and uses thereof Download PDFInfo
- Publication number
- AU2022261654A1 AU2022261654A1 AU2022261654A AU2022261654A AU2022261654A1 AU 2022261654 A1 AU2022261654 A1 AU 2022261654A1 AU 2022261654 A AU2022261654 A AU 2022261654A AU 2022261654 A AU2022261654 A AU 2022261654A AU 2022261654 A1 AU2022261654 A1 AU 2022261654A1
- Authority
- AU
- Australia
- Prior art keywords
- cyclin
- polypeptide
- seq
- nucleic acid
- modified
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4738—Cell cycle regulated proteins, e.g. cyclin, CDC, INK-CCR
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
- C12N15/625—DNA sequences coding for fusion proteins containing a sequence coding for a signal sequence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/095—Fusion polypeptide containing a localisation/targetting motif containing a nuclear export signal
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A40/00—Adaptation technologies in agriculture, forestry, livestock or agroalimentary production
- Y02A40/10—Adaptation technologies in agriculture, forestry, livestock or agroalimentary production in agriculture
- Y02A40/146—Genetically Modified [GMO] plants, e.g. transgenic plants
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Cell Biology (AREA)
- Toxicology (AREA)
- Neurology (AREA)
- Animal Behavior & Ethology (AREA)
- Neurosurgery (AREA)
- Public Health (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Wood Science & Technology (AREA)
- Hospice & Palliative Care (AREA)
- General Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Psychiatry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Marine Sciences & Fisheries (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2021901193 | 2021-04-22 | ||
| AU2021901193A AU2021901193A0 (en) | 2021-04-22 | Modified polypeptides and uses thereof | |
| PCT/AU2022/050366 WO2022221922A1 (en) | 2021-04-22 | 2022-04-22 | Modified polypeptides and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2022261654A1 true AU2022261654A1 (en) | 2023-11-09 |
| AU2022261654A9 AU2022261654A9 (en) | 2023-11-16 |
Family
ID=83723498
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2022261654A Pending AU2022261654A1 (en) | 2021-04-22 | 2022-04-22 | Modified polypeptides and uses thereof |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20240199713A1 (https=) |
| EP (1) | EP4326340A4 (https=) |
| JP (1) | JP2024515307A (https=) |
| CN (1) | CN117241838A (https=) |
| AU (1) | AU2022261654A1 (https=) |
| CA (1) | CA3215808A1 (https=) |
| WO (1) | WO2022221922A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025007194A1 (en) * | 2023-07-05 | 2025-01-09 | Macquarie University | Modulation of gene expression |
| WO2025081231A1 (en) * | 2023-10-16 | 2025-04-24 | Infensa Bioscience Pty Ltd | Inhibitors and uses therefor |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3535403A4 (en) * | 2016-11-07 | 2020-08-12 | MacQuarie University | MODULATION OF PROTEIN ACCUMULATION AND ASSOCIATED USES |
| CA3126918A1 (en) * | 2019-01-14 | 2020-07-23 | President And Fellows Of Harvard College | Methods and compositions for restoring stmn2 levels |
-
2022
- 2022-04-22 WO PCT/AU2022/050366 patent/WO2022221922A1/en not_active Ceased
- 2022-04-22 AU AU2022261654A patent/AU2022261654A1/en active Pending
- 2022-04-22 CN CN202280030397.1A patent/CN117241838A/zh active Pending
- 2022-04-22 EP EP22790612.0A patent/EP4326340A4/en active Pending
- 2022-04-22 CA CA3215808A patent/CA3215808A1/en active Pending
- 2022-04-22 US US18/555,844 patent/US20240199713A1/en active Pending
- 2022-04-22 JP JP2023564671A patent/JP2024515307A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2024515307A (ja) | 2024-04-08 |
| US20240199713A1 (en) | 2024-06-20 |
| CN117241838A (zh) | 2023-12-15 |
| AU2022261654A9 (en) | 2023-11-16 |
| WO2022221922A1 (en) | 2022-10-27 |
| CA3215808A1 (en) | 2022-10-27 |
| EP4326340A4 (en) | 2025-04-16 |
| EP4326340A1 (en) | 2024-02-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7221275B2 (ja) | Aavを送達するための組成物および方法 | |
| US10301366B2 (en) | Compositions and methods for treatment of disorders related to CEP290 | |
| EP2844302A2 (en) | Viral vectors for the treatment of retinal dystrophy | |
| US20220362404A1 (en) | Modulation of cellular viability | |
| CN113710693B (zh) | Dna结合结构域反式激活因子及其用途 | |
| CN116685329B (zh) | 核酸构建体及其用于治疗脊髓性肌肉萎缩症的用途 | |
| US20240199713A1 (en) | Modified polypeptides and uses thereof | |
| US20240424039A1 (en) | Aav-mediated gene transfer for retinopathy | |
| US11866469B2 (en) | DNA binding proteins and uses thereof | |
| KR20210057720A (ko) | Clrn1 관련된 청력 손실 및/또는 시력 손실의 치료 방법 | |
| US12161728B2 (en) | Reducing abnormal accumulation of TDP-43 in motor neurons in amyotrophic lateral sclerosis and/or frontotemporal dementia using a construct encoding cyclin F | |
| WO2025007194A1 (en) | Modulation of gene expression | |
| US20260115325A1 (en) | Methods and compositions for treating corneal wounds | |
| AU2015202046B2 (en) | A humanized model of membrane attack complex (mac) formation on murine retina and compositions, kits and methods for treatment of macular degeneration | |
| EA049748B1 (ru) | Виды генной терапии нейродегенеративных нарушений | |
| JP2023513118A (ja) | 遺伝子療法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| SREP | Specification republished | ||
| DA3 | Amendments made section 104 |
Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE NAME OF THE INVENTOR TO READ CHUNG, ROGER; LEE, ALBERT; RAYNER, STEPHANIE; MORSCH, MARCO AND LUU, LUAN |